A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN)
The "RADIANCE-HTN" Study. A Study of the ReCor Medical Paradise System in Clinical Hypertension
Sponsor: ReCor Medical, Inc.
This observational or N/A phase trial investigates Hypertension and Vascular Diseases and is currently ongoing. ReCor Medical, Inc. leads this study, which shows 30 recorded versions since 2016 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Study Description(click to expand)Subjects with essential hypertension controlled on 1 or 2 antihypertensive medications or uncontrolled on 0-2 antihypertensive medications will be included in the RADIANCE Solo cohort while subjects with treatment resistant hypertension on a minimum of 3 antihypertensive medications will be included in the RADIANCE Trio cohort. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication (SOLO) or despite the presence of a stabilized, single pill, triple, fixed dose antihypertensive medication regimen (TRIO).
Subjects with essential hypertension controlled on 1 or 2 antihypertensive medications or uncontrolled on 0-2 antihypertensive medications will be included in the RADIANCE Solo cohort while subjects with treatment resistant hypertension on a minimum of 3 antihypertensive medications will be included in the RADIANCE Trio cohort. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication (SOLO) or despite the presence of a stabilized, single pill, triple, fixed dose antihypertensive medication regimen (TRIO).
Status Flow
Change History
30 versions recorded-
Apr 21, 2026 — Present [daily]
Active Not Recruiting
Phase: NA → None
-
Sep 2025 — Apr 2026 [monthly]
Active Not Recruiting NA
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Sep 2022 — Jul 2024 [monthly]
Active Not Recruiting NA
▶ Show 25 earlier versions
-
Sep 2021 — Sep 2022 [monthly]
Active Not Recruiting NA
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
-
Mar 2021 — May 2021 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting NA
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting NA
-
May 2020 — Oct 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — May 2020 [monthly]
Recruiting NA
-
Mar 2020 — Apr 2020 [monthly]
Recruiting NA
-
Feb 2020 — Mar 2020 [monthly]
Recruiting NA
-
Oct 2019 — Feb 2020 [monthly]
Recruiting NA
-
May 2019 — Oct 2019 [monthly]
Recruiting NA
-
Jan 2019 — May 2019 [monthly]
Recruiting NA
-
Nov 2018 — Jan 2019 [monthly]
Recruiting NA
-
Aug 2018 — Nov 2018 [monthly]
Recruiting NA
-
Jul 2018 — Aug 2018 [monthly]
Recruiting NA
-
Jun 2018 — Jul 2018 [monthly]
Recruiting NA
-
May 2018 — Jun 2018 [monthly]
Recruiting NA
-
Apr 2018 — May 2018 [monthly]
Recruiting NA
-
Nov 2017 — Apr 2018 [monthly]
Recruiting NA
-
Sep 2017 — Nov 2017 [monthly]
Recruiting NA
-
Jun 2017 — Sep 2017 [monthly]
Recruiting NA
-
Mar 2017 — Jun 2017 [monthly]
Recruiting NA
-
Feb 2017 — Mar 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct populations of hypertensive subjects.
Contact Information
- ReCor Medical, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .